Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL)

Leukemia Research

Volumn 32, Issue 5, 2008, Pages 689-690

  Buonamici, Silvia ^a   Aifantis, Iannis ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; HEXAMETHYLENEBISACETAMIDE; NOTCH1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE PHASE; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG EFFICACY; DRUG INHIBITION; EDITORIAL; HUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE;

ACETAMIDES; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL;

EID: 40149083874     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.018     Document Type: Editorial

References (12)

1. Cecchinato V., Erba E., Basile A., Scarpati B., Fazi C., Brando B., et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res 32 (2008) 391-397
2. Marks P.A., Richon V.M., and Rifkind R.A. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: molecular and clinical studies employing hybrid polar compounds. Int J Hematol 63 1 (1996) 1-17
3. Marks P.A., Richon V.M., Kiyokawa H., and Rifkind RA. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci USA 91 22 (1994) 10251-10254
4. Shelly L.L., Fuchs C., and Miele L. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem 73 2 (1999) 164-175
5. Grabher C., von Boehmer H., and Look A.T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6 5 (2006) 347-359
6. Weng A.P., Weng A.P., Ferrando A.A., Lee W., Morris JPth, Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 5694 (2004) 269-271
7. Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 204 8 (2007) 1825-1835
8. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204 8 (2007) 1813-1824
9. Young C.W., Fanucchi M.P., Declan Walsh T., Baltzer L., Yaldaei S., Stevens Y.W., et al. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res 48 24 Pt 1 (1988) 7304-7309
10. Conley B.A., Forrest A., Egorin M.J., Zuhowski E.G., Sinibaldi V., and Van Echo DA. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 49 12 (1989) 3436-3440
11. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., and Wierda W.G. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood (2007)
12. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 1 (2007) 31-39